| 4.84 0.1 (2.11%) | 06-18 09:48 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.53  |
1-year : | 8.17 |
| Resists | First : | 5.59 |
Second : | 6.99 |
| Pivot price | 4.77 |
|||
| Supports | First : | 3.32 | Second : | 2.77 |
| MAs | MA(5) : | 4.56  |
MA(20) : | 5.11 |
| MA(100) : | 5.62 |
MA(250) : | 3.46 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 42.8 |
D(3) : | 42.3 |
| RSI | RSI(14): 42.7 |
|||
| 52-week | High : | 8.32 | Low : | 0.71 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ STTK ] has closed above bottom band by 48.4%. Bollinger Bands are 52.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.76 - 4.78 | 4.78 - 4.8 |
| Low: | 4.3 - 4.32 | 4.32 - 4.34 |
| Close: | 4.7 - 4.74 | 4.74 - 4.78 |
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Thu, 18 Jun 2026
Shattuck Labs Inc (STTK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Thu, 18 Jun 2026
Shattuck Labs Inc (STTK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Wed, 17 Jun 2026
Shattuck Labs Inc (STTK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Wed, 17 Jun 2026
Deep Track group reports 5.17% stake in Shattuck Labs (STTK) via warrants - Stock Titan
Mon, 15 Jun 2026
OrbiMed funds add STTK pre-funded warrants in June 2026 stock offering - Stock Titan
Mon, 15 Jun 2026
[SCHEDULE 13D/A] Shattuck Labs, Inc. Amended Major Shareholder Report - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 96 (M) |
| Held by Insiders | 4.771e+007 (%) |
| Held by Institutions | 4.4 (%) |
| Shares Short | 1,420 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.894e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 258.2 % |
| Return on Equity (ttm) | -36.7 % |
| Qtrly Rev. Growth | 1e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -56 |
| EBITDA (p.s.) | -2.73394e+006 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -41 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.09 |
| Price to Cash Flow | 4.06 |
| Dividend | 0 |
| Forward Dividend | 1.15e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|